Hailan Pharmaceutical: Daunzaluhang Soft Capsules Approved for Market Launch

Hengrui Pharmaceutical announced on the evening of May 29th that its independently developed new drug, Hai Na An, has been approved by the National Medical Products Administration for listing. It is used to treat adult patients with metastatic castration-resistant prostate cancer who have received enzalutamide and chemotherapy and have disease progression, and have not previously received new types of androgen receptor inhibitors.